Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 448

1.

Purging with Chlorambucil to prevent infusion-related reactions before Obinutuzumab administration: a monocentric pilot experience.

Autore F, Fresa A, Innocenti I, Tomasso A, Morelli F, Corbingi A, Sorà F, Laurenti L.

Hematol Oncol. 2019 Oct 11. doi: 10.1002/hon.2684. [Epub ahead of print]

PMID:
31604368
2.

New developments in the treatment of follicular lymphoma.

Leonard JP.

Rinsho Ketsueki. 2019;60(9):1199-1204. doi: 10.11406/rinketsu.60.1199.

PMID:
31597844
3.

The evolving treatment landscape of chronic lymphocytic leukemia.

Schiattone L, Ghia P, Scarfò L.

Curr Opin Oncol. 2019 Nov;31(6):568-573. doi: 10.1097/CCO.0000000000000585.

PMID:
31593975
4.

Current targeted therapies in lymphomas.

Chung C.

Am J Health Syst Pharm. 2019 Oct 3. pii: zxz202. doi: 10.1093/ajhp/zxz202. [Epub ahead of print]

PMID:
31580408
5.

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Del Giudice I, Raponi S, Della Starza I, De Propris MS, Cavalli M, De Novi LA, Cappelli LV, Ilari C, Cafforio L, Guarini A, Foà R.

Front Oncol. 2019 Aug 29;9:689. doi: 10.3389/fonc.2019.00689. eCollection 2019. Review.

6.

Broadening and Enhancing Functions of Antibodies by Self-Assembling Multimerization at Cell Surface.

Li L, Wang J, Li Y, Radford DC, Yang J, Kopeček J.

ACS Nano. 2019 Oct 3. doi: 10.1021/acsnano.9b04868. [Epub ahead of print]

PMID:
31553883
7.

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.

Agez M, Mandon ED, Iwema T, Gianotti R, Limani F, Herter S, Mössner E, Kusznir EA, Huber S, Lauer M, Ringler P, Ferrara C, Klein C, Jawhari A.

Sci Rep. 2019 Sep 23;9(1):13675. doi: 10.1038/s41598-019-50031-4.

8.

The role of obinutuzumab in the management of follicular lymphoma.

O'Nions J, Townsend W.

Future Oncol. 2019 Sep 20. doi: 10.2217/fon-2019-0193. [Epub ahead of print]

PMID:
31538821
9.

A systematic review of the efficacy of CNS prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era.

Eyre TA, Djebbari F, Kirkwood AA, Collins GP.

Haematologica. 2019 Sep 5. pii: haematol.2019.229948. doi: 10.3324/haematol.2019.229948. [Epub ahead of print]

10.

Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia.

Stephens DM.

Blood. 2019 Sep 5. pii: blood.2019001750. doi: 10.1182/blood.2019001750. [Epub ahead of print]

PMID:
31488409
12.

Chronic lymphocytic leukemia paradigm continues to be refined: news from the American Society of Hematology 2018 annual meeting.

Molica S.

Int J Hematol Oncol. 2019 May 31;8(2):IJH14. doi: 10.2217/ijh-2019-0001. eCollection 2019 Aug.

13.

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0559-9. [Epub ahead of print]

PMID:
31462735
14.

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.

Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, Zaritskey A, Merot JL, Tausch E, Trunzer K, Robson S, Gresko E, Böttcher S, Foà R, Stilgenbauer S, Leblond V.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0554-1. [Epub ahead of print]

PMID:
31455851
15.

Frontline therapies for untreated chronic lymphoid leukemia.

Liu D, Zhao J.

Exp Hematol Oncol. 2019 Aug 17;8:15. doi: 10.1186/s40164-019-0139-8. eCollection 2019. Review.

16.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG.

Haematologica. 2019 Aug 14. pii: haematol.2019.223743. doi: 10.3324/haematol.2019.223743. [Epub ahead of print]

17.

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.

Albertsson-Lindblad A, Freiburghaus C, Jerkeman M, Ek S.

Exp Hematol Oncol. 2019 Aug 6;8:16. doi: 10.1186/s40164-019-0141-1. eCollection 2019.

18.

Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.

Focosi D, Tuccori M, Maggi F.

Rev Med Virol. 2019 Aug 1:e2077. doi: 10.1002/rmv.2077. [Epub ahead of print] Review.

PMID:
31369199
19.

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.

Hallek M.

Am J Hematol. 2019 Nov;94(11):1266-1287. doi: 10.1002/ajh.25595. Epub 2019 Oct 4.

PMID:
31364186
20.

PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species.

Grimm HP, Schick E, Hainzl D, Justies N, Yu L, Klein C, Husar E, Richter WF.

J Pharm Sci. 2019 Nov;108(11):3729-3736. doi: 10.1016/j.xphs.2019.07.013. Epub 2019 Jul 25.

PMID:
31351865

Supplemental Content

Loading ...
Support Center